<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: To assess the prognostic significance of screening for <z:e sem="disease" ids="C0037315" disease_type="Disease or Syndrome" abbrv="">sleep-disordered breathing</z:e> in patients with implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) with regard to appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy and total mortality </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS AND RESULTS: Overnight sleep studies were performed in 204 ICD recipients not known to have <z:hpo ids='HP_0010535'>sleep apnoea</z:hpo> and with no history of daytime sleepiness </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0037315" disease_type="Disease or Syndrome" abbrv="">Sleep-disordered breathing</z:e> was diagnosed in the presence of an <z:hpo ids='HP_0002104'>apnoea</z:hpo>-<z:mp ids='MP_0001956'>hypopnea</z:mp> index of five or more events per hour </plain></SENT>
<SENT sid="3" pm="."><plain>Seventy patients (34%) had no <z:hpo ids='HP_0010535'>sleep apnoea</z:hpo>, 105 patients (51%) had <z:hpo ids='HP_0010536'>central sleep apnoea</z:hpo>, and 29 patients (14%) had obstructive <z:hpo ids='HP_0010535'>sleep apnoea</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>During 38 Â± 26 months follow-up, 80 patients (39%) received appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy for <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> (VT) or <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e>), and 54 patients (26%) died </plain></SENT>
<SENT sid="5" pm="."><plain>On multivariate Cox regression analysis, age, left ventricular (LV) end-diastolic diameter, secondary prevention <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> indication, use of <z:chebi fb="40" ids="35498">diuretics</z:chebi>, and absence of <z:chebi fb="0" ids="27584,30834">aldosterone</z:chebi> <z:chebi fb="68" ids="48706">antagonist</z:chebi> therapy but not <z:hpo ids='HP_0010535'>sleep apnoea</z:hpo> were associated with appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy for VT or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VF</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, multivariate Cox analysis identified age and LV ejection fraction but not <z:hpo ids='HP_0010535'>sleep apnoea</z:hpo> as predictors of total mortality </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Undiagnosed <z:e sem="disease" ids="C0037315" disease_type="Disease or Syndrome" abbrv="">sleep-disordered breathing</z:e> is common in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> recipients </plain></SENT>
<SENT sid="8" pm="."><plain>The presence and severity of previously unknown <z:hpo ids='HP_0010535'>sleep apnoea</z:hpo> in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> recipients, however, does not appear to be an independent predictor of appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy or morality during follow-up </plain></SENT>
</text></document>